C
Carlo M. Croce
Researcher at Ohio State University
Publications - 1156
Citations - 199822
Carlo M. Croce is an academic researcher from Ohio State University. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 198, co-authored 1135 publications receiving 189007 citations. Previous affiliations of Carlo M. Croce include University of Nebraska Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma.
Cory Pettit,Amy Webb,Steve Walston,Moumita Chatterjee,Wei Chen,Wendy L. Frankel,Carlo M. Croce,Terence M. Williams +7 more
TL;DR: This study identified miRNAs (miRs) that were differentially expressed between pre- and post-CRT tumor samples, and these miRs implicated multiple signaling pathways that may confer resistance to CRT.
Journal ArticleDOI
Crystal structures of Tcl1 family oncoproteins and their conserved surface features.
John M. Petock,Ivan Y. Torshin,Yuan-Fang Wang,Garrett C. Du Bois,Carlo M. Croce,Robert W. Harrison,Irene T. Weber +6 more
TL;DR: Members of the TCL1 family of oncogenes are abnormally expressed in mature T-cell leukemias and B-cell lymphomas and the structures revealed conserved semi-planar surfaces that have characteristics of surfaces involved in protein-protein interactions.
Journal ArticleDOI
The long journey of TCL1 transgenic mice: lessons learned in the last 15 years.
TL;DR: The main features of the original TCL1 models and the different lines of research successively developed are discussed with particular attention to genetically compound mice and the therapeutic applications in drug development.
Journal ArticleDOI
Primary intrathyroidal paraganglioma: histopathology and novel molecular alterations
TL;DR: This is the first example of intrathyroidal paraganglioma to be analyzed for both mutations and for single nucleotide polymorphisms in PGL1 and SDH loci and the presence of these genetic abnormalities may have therapeutic implications.
Journal ArticleDOI
Effect of a new De-N-acetyl-lysoglycosphingolipid on chemically-induced inflammatory bowel disease: possible mechanism of action
TL;DR: A new, orally active de-N-acetylated lysoglycosphingolipid (WILD20) was evaluated as antiinflammatory agent using a model of chemically-induced inflammatory bowel disease (IBD) in the rat to mimic human ulcerative colitis and Chron's disease.